Research topics - Understanding the response to AR inhibition of de novo metastatic disease
Patients who present with de novo metastatic prostate cancer at the time point of diagnosis have a much more aggressive disease than patients who metastasize after treatment of their primary tumor. That said, de novo metastatic disease is highly heterogeneous in terms of therapy responses. Using molecular and clinical data of de novo metastatic prostate cancer, we aim to predict responses in this setting using an integrated approach.
